Ruxolitinib for Chronic Graft-versus-Host Disease. Reply
N Engl J Med
.
2021 Oct 21;385(17):1631-1632.
doi: 10.1056/NEJMc2113499.
Authors
Robert Zeiser
1
,
Takanori Teshima
2
,
Franco Locatelli
3
Affiliations
1
University of Freiburg, Freiburg, Germany robert.zeiser@uniklinik-freiburg.de.
2
Hokkaido University, Sapporo, Japan.
3
Ospedale Pediatrico Bambino Gesù, Rome, Italy.
PMID:
34670053
DOI:
10.1056/NEJMc2113499
No abstract available
Publication types
Letter
Comment
MeSH terms
Graft vs Host Disease* / drug therapy
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Nitriles
Pyrazoles / therapeutic use
Pyrimidines
Substances
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib